{"parse":{"title":"Biopharmaceutical","pageid":2654847,"revid":851520426,"text":{"*":"<div class=\"mw-parser-output\"><p>A <b>biopharmaceutical</b>, also known as a <b>biologic(al) medical product</b>, <b>biological</b>,<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> or <b>biologic</b>, is any <a href=\"/wiki/Pharmaceutical_drug\" class=\"mw-redirect\" title=\"Pharmaceutical drug\">pharmaceutical drug</a> product manufactured in, extracted from, or <a href=\"/wiki/Semisynthesis\" title=\"Semisynthesis\">semisynthesized</a> from <a href=\"/wiki/Biology\" title=\"Biology\">biological</a> sources. Different from <a href=\"/wiki/Total_synthesis\" title=\"Total synthesis\">totally synthesized</a> pharmaceuticals, they include <a href=\"/wiki/Vaccine\" title=\"Vaccine\">vaccines</a>, <a href=\"/wiki/Blood\" title=\"Blood\">blood</a>, blood components, <a href=\"/wiki/Allergenic\" class=\"mw-redirect\" title=\"Allergenic\">allergenics</a>, <a href=\"/wiki/Somatic_cell\" title=\"Somatic cell\">somatic cells</a>, <a href=\"/wiki/Gene_therapy\" title=\"Gene therapy\">gene therapies</a>, <a href=\"/wiki/Tissue_(biology)\" title=\"Tissue (biology)\">tissues</a>, <a href=\"/wiki/Recombinant_proteins\" class=\"mw-redirect\" title=\"Recombinant proteins\">recombinant therapeutic protein</a>, and living <a href=\"/wiki/Cell_(biology)\" title=\"Cell (biology)\">cells</a> used in <a href=\"/wiki/Cell_therapy\" title=\"Cell therapy\">cell therapy</a>. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their <a href=\"/wiki/Precursor_(chemistry)\" title=\"Precursor (chemistry)\">precursors</a> or components) are isolated from <a href=\"/wiki/Life\" title=\"Life\">living</a> sources\u2014human, animal, plant, fungal, or microbial.\n</p><p>Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. Some <a href=\"/wiki/Regulatory_agency\" title=\"Regulatory agency\">regulatory agencies</a> use the terms <i>biological medicinal products</i> or <i>therapeutic biological product</i> to refer specifically to engineered <a href=\"/wiki/Macromolecule\" title=\"Macromolecule\">macromolecular</a> products like protein- and <a href=\"/wiki/Nucleic_acid\" title=\"Nucleic acid\">nucleic acid</a>-based <a href=\"/wiki/Drug\" title=\"Drug\">drugs</a>, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source.<sup id=\"cite_ref-pmid18612293_2-0\" class=\"reference\"><a href=\"#cite_note-pmid18612293-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> <a href=\"/wiki/Specialty_drugs\" class=\"mw-redirect\" title=\"Specialty drugs\">Specialty drugs</a>, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics.<sup id=\"cite_ref-ncbi_2013_5-0\" class=\"reference\"><a href=\"#cite_note-ncbi_2013-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-nytimes.com_2015_07_16_6-0\" class=\"reference\"><a href=\"#cite_note-nytimes.com_2015_07_16-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-UofW_7-0\" class=\"reference\"><a href=\"#cite_note-UofW-7\">&#91;7&#93;</a></sup> The <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> uses the term <i>advanced therapy medicinal products</i> (ATMPs) for medicines for human use that are \"based on genes, cells, or tissue engineering\",<sup id=\"cite_ref-EMA_CAT_8-0\" class=\"reference\"><a href=\"#cite_note-EMA_CAT-8\">&#91;8&#93;</a></sup> including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof.<sup id=\"cite_ref-EMA_ATMPs_9-0\" class=\"reference\"><a href=\"#cite_note-EMA_ATMPs-9\">&#91;9&#93;</a></sup> Within EMA contexts, the term <i>advanced therapies</i> refers specifically to ATMPs, although that term is rather nonspecific outside those contexts.\n</p><p>Gene-based and cellular biologics, for example, often are at the forefront of <a href=\"/wiki/Biomedical\" class=\"mw-redirect\" title=\"Biomedical\">biomedical</a> research, and may be used to treat a variety of medical conditions for which no other treatments are available.<sup id=\"cite_ref-FDA_FAQ_10-0\" class=\"reference\"><a href=\"#cite_note-FDA_FAQ-10\">&#91;10&#93;</a></sup>\n</p><p>In some jurisdictions, biologics are regulated via different pathways than other small molecule drugs and <a href=\"/wiki/Medical_devices\" class=\"mw-redirect\" title=\"Medical devices\">medical devices</a>.<sup id=\"cite_ref-pmid18958946_11-0\" class=\"reference\"><a href=\"#cite_note-pmid18958946-11\">&#91;11&#93;</a></sup>\n</p><p>The term <b>biopharmacology</b> is sometimes used to describe the branch of pharmacology that studies biopharmaceuticals.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Major_classes\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Major classes</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Extracted_from_living_systems\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Extracted from living systems</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Produced_by_recombinant_DNA\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Produced by recombinant DNA</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Vaccines\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Vaccines</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Gene_therapy\"><span class=\"tocnumber\">1.4</span> <span class=\"toctext\">Gene therapy</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Biosimilars\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Biosimilars</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Commercialization\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Commercialization</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Large-scale_production\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Large-scale production</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Transgenics\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Transgenics</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Regulation\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Regulation</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-11\"><a href=\"#European_Union\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">European Union</span></a></li>\n<li class=\"toclevel-2 tocsection-12\"><a href=\"#United_States\"><span class=\"tocnumber\">5.2</span> <span class=\"toctext\">United States</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-13\"><a href=\"#See_also\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-14\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-15\"><a href=\"#External_links\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Major_classes\">Major classes</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=1\" title=\"Edit section: Major classes\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:122px;\"><a href=\"/wiki/File:FreshFrozenPlasma.JPG\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1d/FreshFrozenPlasma.JPG/120px-FreshFrozenPlasma.JPG\" width=\"120\" height=\"154\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1d/FreshFrozenPlasma.JPG/180px-FreshFrozenPlasma.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1d/FreshFrozenPlasma.JPG/240px-FreshFrozenPlasma.JPG 2x\" data-file-width=\"1633\" data-file-height=\"2090\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:FreshFrozenPlasma.JPG\" class=\"internal\" title=\"Enlarge\"></a></div><a href=\"/wiki/Blood_plasma\" title=\"Blood plasma\">Blood plasma</a> is a type of biopharmaceutical directly extracted from living systems.</div></div></div>\n<h3><span class=\"mw-headline\" id=\"Extracted_from_living_systems\">Extracted from living systems</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=2\" title=\"Edit section: Extracted from living systems\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Some of the oldest forms of biologics are extracted from the bodies of animals, and other humans especially. Important biologics include:\n</p>\n<ul><li><a href=\"/wiki/Whole_blood\" title=\"Whole blood\">Whole blood</a> and other blood components</li>\n<li><a href=\"/wiki/Organ_transplantation\" title=\"Organ transplantation\">Organs</a> and <a href=\"/wiki/Tissue_transplant\" class=\"mw-redirect\" title=\"Tissue transplant\">tissue transplants</a></li>\n<li><a href=\"/wiki/Stem_cell_therapy\" class=\"mw-redirect\" title=\"Stem cell therapy\">Stem cell therapy</a></li>\n<li><a href=\"/wiki/Antibodies\" class=\"mw-redirect\" title=\"Antibodies\">Antibodies</a> for <a href=\"/wiki/Passive_immunization\" class=\"mw-redirect\" title=\"Passive immunization\">passive immunization</a> (e.g., to treat a <a href=\"/wiki/Virus\" title=\"Virus\">virus</a> infection)</li>\n<li><a href=\"/wiki/Breast_milk\" title=\"Breast milk\">Human breast milk</a></li>\n<li><a href=\"/wiki/Fecal_microbiota_transplant\" title=\"Fecal microbiota transplant\">Fecal microbiota</a></li>\n<li><a href=\"/wiki/Human_fertilization\" title=\"Human fertilization\">Human reproductive cells</a></li></ul>\n<p>Some biologics that were previously extracted from animals, such as insulin, are now more commonly produced by <a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">recombinant DNA</a>.\n</p>\n<h3><span class=\"mw-headline\" id=\"Produced_by_recombinant_DNA\">Produced by recombinant DNA</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=3\" title=\"Edit section: Produced by recombinant DNA\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">See also: <a href=\"/wiki/Biologics_for_immunosuppression\" title=\"Biologics for immunosuppression\">Biologics for immunosuppression</a></div>\n<p>As indicated the term \"biologics\" can be used to refer to a wide range of biological products in medicine. However, in most cases, the term \"biologics\" is used more restrictively for a class of therapeutics (either approved or in development) that are produced by means of biological processes involving <a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">recombinant DNA</a> technology. These medications are usually one of three types:\n</p>\n<ol><li>Substances that are (nearly) identical to the body's own key signalling proteins. Examples are the blood-production stimulating protein <a href=\"/wiki/Erythropoetin\" class=\"mw-redirect\" title=\"Erythropoetin\">erythropoetin</a>, or the growth-stimulating hormone named (simply) \"<a href=\"/wiki/Growth_hormone\" title=\"Growth hormone\">growth hormone</a>\" or biosynthetic human <a href=\"/wiki/Insulin\" title=\"Insulin\">insulin</a> and its analogues.</li>\n<li><a href=\"/wiki/Monoclonal_antibodies\" class=\"mw-redirect\" title=\"Monoclonal antibodies\">Monoclonal antibodies</a>. These are similar to the antibodies that the human immune system uses to fight off bacteria and viruses, but they are \"custom-designed\" (using <a href=\"/wiki/Hybridoma\" class=\"mw-redirect\" title=\"Hybridoma\">hybridoma</a> technology or other methods) and can therefore be made specifically to counteract or block any given substance in the body, or to target any specific cell type; examples of such monoclonal antibodies for use in various diseases are given in the table below.</li>\n<li>Receptor constructs (<a href=\"/wiki/Fusion_protein\" title=\"Fusion protein\">fusion proteins</a>), usually based on a naturally occurring receptor linked to the <a href=\"/wiki/Immunoglobulin\" class=\"mw-redirect\" title=\"Immunoglobulin\">immunoglobulin</a> frame. In this case, the receptor provides the construct with detailed specificity, whereas the immunoglobulin-structure imparts stability and other useful features in terms of <a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">pharmacology</a>. Some examples are listed in the table below.</li></ol>\n<p>Biologics as a class of medications in this narrower sense have had a profound impact on many medical fields, primarily <a href=\"/wiki/Rheumatology\" title=\"Rheumatology\">rheumatology</a> and <a href=\"/wiki/Oncology\" title=\"Oncology\">oncology</a>, but also <a href=\"/wiki/Cardiology\" title=\"Cardiology\">cardiology</a>, <a href=\"/wiki/Dermatology\" title=\"Dermatology\">dermatology</a>, <a href=\"/wiki/Gastroenterology\" title=\"Gastroenterology\">gastroenterology</a>, <a href=\"/wiki/Neurology\" title=\"Neurology\">neurology</a>, and others. In most of these disciplines, biologics have added major therapeutic options for the treatment of many diseases, including some for which no effective therapies were available, and others where previously existing therapies were clearly inadequate. However, the advent of biologic therapeutics has also raised complex regulatory issues (see below), and significant pharmacoeconomic concerns, because the cost for biologic therapies has been dramatically higher than for conventional (pharmacological) medications. This factor has been particularly relevant since many biological medications are used for the treatment of <a href=\"/wiki/Chronic_diseases\" class=\"mw-redirect\" title=\"Chronic diseases\">chronic diseases</a>, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of otherwise untreatable cancer during the remainder of life. The cost of treatment with a typical monoclonal antibody therapy for relatively common indications is generally in the range of \u20ac7,000\u201314,000 per patient per year.\n</p><p>Older patients who receive biologic therapy for diseases such as <a href=\"/wiki/Rheumatoid_arthritis\" title=\"Rheumatoid arthritis\">rheumatoid arthritis</a>, <a href=\"/wiki/Psoriatic_arthritis\" title=\"Psoriatic arthritis\">psoriatic arthritis</a>, or <a href=\"/wiki/Ankylosing_spondylitis\" title=\"Ankylosing spondylitis\">ankylosing spondylitis</a> are at increased risk for life-threatening infection, adverse cardiovascular events, and <a href=\"/wiki/Malignancy\" title=\"Malignancy\">malignancy</a>.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p><p>The first such substance approved for therapeutic use was biosynthetic \"human\" <a href=\"/wiki/Insulin\" title=\"Insulin\">insulin</a> made via <a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">recombinant DNA</a>. Sometimes referred to as rHI, under the <a href=\"/wiki/Trade_name\" title=\"Trade name\">trade name</a> <a href=\"/wiki/Humulin\" class=\"mw-redirect\" title=\"Humulin\">Humulin</a>, was developed by <a href=\"/wiki/Genentech\" title=\"Genentech\">Genentech</a>, but licensed to <a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly and Company</a>, who manufactured and marketed it starting in 1982.\n</p><p>Major kinds of biopharmaceuticals include:\n</p>\n<ul><li>Blood factors (<a href=\"/wiki/Factor_VIII\" title=\"Factor VIII\">Factor VIII</a> and <a href=\"/wiki/Factor_IX\" title=\"Factor IX\">Factor IX</a>)</li>\n<li>Thrombolytic agents (<a href=\"/wiki/Tissue_plasminogen_activator\" title=\"Tissue plasminogen activator\">tissue plasminogen activator</a>)</li>\n<li><a href=\"/wiki/Hormones\" class=\"mw-redirect\" title=\"Hormones\">Hormones</a> (<a href=\"/wiki/Insulin\" title=\"Insulin\">insulin</a>, glucagon, growth hormone, gonadotrophins)</li>\n<li>Haematopoietic growth factors (<a href=\"/wiki/Erythropoietin\" title=\"Erythropoietin\">Erythropoietin</a>, <a href=\"/wiki/Colony_stimulating_factors\" class=\"mw-redirect\" title=\"Colony stimulating factors\">colony stimulating factors</a>)</li>\n<li><a href=\"/wiki/Interferons\" class=\"mw-redirect\" title=\"Interferons\">Interferons</a> (Interferons-\u03b1, -\u03b2, -\u03b3)</li>\n<li><a href=\"/wiki/Interleukin\" title=\"Interleukin\">Interleukin</a>-based products (Interleukin-2)</li>\n<li><a href=\"/wiki/Vaccines\" class=\"mw-redirect\" title=\"Vaccines\">Vaccines</a> (<a href=\"/wiki/Hepatitis_B\" title=\"Hepatitis B\">Hepatitis B</a> surface <a href=\"/wiki/Antigen\" title=\"Antigen\">antigen</a>)</li>\n<li><a href=\"/wiki/Monoclonal_antibodies\" class=\"mw-redirect\" title=\"Monoclonal antibodies\">Monoclonal antibodies</a> (Various)</li>\n<li>Additional products (<a href=\"/wiki/Tumour_necrosis_factor\" class=\"mw-redirect\" title=\"Tumour necrosis factor\">tumour necrosis factor</a>, therapeutic enzymes)</li></ul>\n<p>Research and development investment in new medicines by the biopharmaceutical industry stood at $65.2 billion in 2008.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> A few examples of biologics made with <a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">recombinant DNA</a> technology include:\n</p>\n<table class=\"wikitable\">\n<tbody><tr>\n<th><a href=\"/wiki/United_States_Adopted_Name\" title=\"United States Adopted Name\">USAN</a>/<a href=\"/wiki/International_Nonproprietary_Name\" class=\"mw-redirect\" title=\"International Nonproprietary Name\">INN</a>\n</th>\n<th>Trade name\n</th>\n<th>Indication\n</th>\n<th>Technology\n</th>\n<th>Mechanism of action\n</th></tr>\n<tr>\n<td><a href=\"/wiki/Abatacept\" title=\"Abatacept\">abatacept</a>\n</td>\n<td>Orencia\n</td>\n<td><a href=\"/wiki/Rheumatoid_arthritis\" title=\"Rheumatoid arthritis\">rheumatoid arthritis</a>\n</td>\n<td><a href=\"/wiki/Immunoglobin\" class=\"mw-redirect\" title=\"Immunoglobin\">immunoglobin</a> <a href=\"/wiki/CTLA-4\" title=\"CTLA-4\">CTLA-4</a> <a href=\"/wiki/Fusion_protein\" title=\"Fusion protein\">fusion protein</a>\n</td>\n<td><a href=\"/wiki/T-cell\" class=\"mw-redirect\" title=\"T-cell\">T-cell</a> deactivation\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Adalimumab\" title=\"Adalimumab\">adalimumab</a>\n</td>\n<td>Humira\n</td>\n<td>rheumatoid arthritis, <a href=\"/wiki/Ankylosing_spondylitis\" title=\"Ankylosing spondylitis\">ankylosing spondylitis</a>, <a href=\"/wiki/Psoriatic_arthritis\" title=\"Psoriatic arthritis\">psoriatic arthritis</a>, psoriasis, <a href=\"/wiki/Ulcerative_colitis\" title=\"Ulcerative colitis\">ulcerative colitis</a>, <a href=\"/wiki/Crohn%27s_disease\" title=\"Crohn&#39;s disease\">Crohn's disease</a>\n</td>\n<td><a href=\"/wiki/Monoclonal_antibody\" title=\"Monoclonal antibody\">monoclonal antibody</a>\n</td>\n<td><a href=\"/wiki/Tumor_necrosis_factor-alpha\" class=\"mw-redirect\" title=\"Tumor necrosis factor-alpha\">TNF</a> <a href=\"/wiki/Receptor_antagonist\" title=\"Receptor antagonist\">antagonist</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Alefacept\" title=\"Alefacept\">alefacept</a>\n</td>\n<td>Amevive\n</td>\n<td>chronic plaque <a href=\"/wiki/Psoriasis\" title=\"Psoriasis\">psoriasis</a>\n</td>\n<td>immunoglobin G1 fusion protein\n</td>\n<td>incompletely characterized\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Erythropoietin\" title=\"Erythropoietin\">erythropoietin</a>\n</td>\n<td>Epogen\n</td>\n<td><a href=\"/wiki/Anemia\" title=\"Anemia\">anemia</a> arising from cancer <a href=\"/wiki/Chemotherapy\" title=\"Chemotherapy\">chemotherapy</a>, <a href=\"/wiki/Chronic_renal_failure\" class=\"mw-redirect\" title=\"Chronic renal failure\">chronic renal failure</a>, etc.\n</td>\n<td><a href=\"/wiki/Recombinant_protein\" class=\"mw-redirect\" title=\"Recombinant protein\">recombinant protein</a>\n</td>\n<td>stimulation of red blood cell production\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Etanercept\" title=\"Etanercept\">etanercept</a>\n</td>\n<td>Enbrel\n</td>\n<td>rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis\n</td>\n<td>recombinant human TNF-receptor fusion protein\n</td>\n<td>TNF antagonist\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Infliximab\" title=\"Infliximab\">infliximab</a>\n</td>\n<td>Remicade\n</td>\n<td>rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Ulcerative Colitus, <a href=\"/wiki/Crohn%27s_disease\" title=\"Crohn&#39;s disease\">Crohn's disease</a>\n</td>\n<td>monoclonal antibody\n</td>\n<td>TNF antagonist\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Trastuzumab\" title=\"Trastuzumab\">trastuzumab</a>\n</td>\n<td>Herceptin\n</td>\n<td><a href=\"/wiki/Breast_cancer\" title=\"Breast cancer\">breast cancer</a>\n</td>\n<td><a href=\"/wiki/Humanized_antibodies\" class=\"mw-redirect\" title=\"Humanized antibodies\">humanized</a> monoclonal antibody\n</td>\n<td><a href=\"/wiki/HER2/neu\" title=\"HER2/neu\">HER2/neu</a> (erbB2) antagonist\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Ustekinumab\" title=\"Ustekinumab\">ustekinumab</a>\n</td>\n<td>Stelara\n</td>\n<td><a href=\"/wiki/Psoriasis\" title=\"Psoriasis\">psoriasis</a>\n</td>\n<td><a href=\"/wiki/Humanized_antibodies\" class=\"mw-redirect\" title=\"Humanized antibodies\">humanized</a> monoclonal antibody\n</td>\n<td>IL-12 and IL-23 antagonist\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Denileukin_diftitox\" title=\"Denileukin diftitox\">denileukin diftitox</a>\n</td>\n<td>Ontak\n</td>\n<td>cutaneous T-cell lymphoma (CTCL)\n</td>\n<td>Diphtheria toxin engineered protein combining Interleukin-2 and Diphtheria toxin\n</td>\n<td><a href=\"/wiki/Interleukin-2\" class=\"mw-redirect\" title=\"Interleukin-2\">Interleukin-2</a> receptor binder\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Golimumab\" title=\"Golimumab\">golimumab</a>\n</td>\n<td>Simponi\n</td>\n<td><a href=\"/wiki/Rheumatoid_arthritis\" title=\"Rheumatoid arthritis\">rheumatoid arthritis</a>, <a href=\"/wiki/Psoriatic_arthritis\" title=\"Psoriatic arthritis\">psoriatic arthritis</a>, <a href=\"/wiki/Ankylosing_spondylitis\" title=\"Ankylosing spondylitis\">ankylosing spondylitis</a>, <a href=\"/wiki/Ulcerative_colitis\" title=\"Ulcerative colitis\">ulcerative colitis</a>\n</td>\n<td><a href=\"/wiki/Monoclonal_antibody\" title=\"Monoclonal antibody\">monoclonal antibody</a>\n</td>\n<td><a href=\"/wiki/Tumor_necrosis_factor-alpha\" class=\"mw-redirect\" title=\"Tumor necrosis factor-alpha\">TNF</a> <a href=\"/wiki/Receptor_antagonist\" title=\"Receptor antagonist\">antagonist</a>\n</td></tr>\n</tbody></table>\n<h3><span class=\"mw-headline\" id=\"Vaccines\">Vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=4\" title=\"Edit section: Vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Vaccine\" title=\"Vaccine\">Vaccine</a></div>\n<p>Many vaccines are grown in tissue cultures.\n</p>\n<h3><span class=\"mw-headline\" id=\"Gene_therapy\">Gene therapy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=5\" title=\"Edit section: Gene therapy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Viral_gene_therapy\" class=\"mw-redirect\" title=\"Viral gene therapy\">Viral gene therapy</a> involves artificially manipulating a <a href=\"/wiki/Virus\" title=\"Virus\">virus</a> to include a desirable piece of genetic material.\n</p>\n<h2><span class=\"mw-headline\" id=\"Biosimilars\">Biosimilars</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=6\" title=\"Edit section: Biosimilars\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Biosimilars\" class=\"mw-redirect\" title=\"Biosimilars\">Biosimilars</a></div>\n<p>With the expiration of numerous <a href=\"/wiki/Patents\" class=\"mw-redirect\" title=\"Patents\">patents</a> for <a href=\"/wiki/Blockbuster_drug\" class=\"mw-redirect\" title=\"Blockbuster drug\">blockbuster biologics</a> between 2012 and 2019, the interest in biosimilar production, i.e., follow-on biologics, has increased.<sup id=\"cite_ref-biosimilars_14-0\" class=\"reference\"><a href=\"#cite_note-biosimilars-14\">&#91;14&#93;</a></sup> Compared to <a href=\"/wiki/Small_molecules\" class=\"mw-redirect\" title=\"Small molecules\">small molecules</a> that consist of chemically identical <a href=\"/wiki/Active_ingredients\" class=\"mw-redirect\" title=\"Active ingredients\">active ingredients</a>, biologics are vastly more complex and consist of a multitude of subspecies. Due to their heterogeneity and the high process sensitivity, originators and follow-on biosimilars will exhibit variability in specific variants over time, however the safety and clinical performance of both originator and biosimilar biopharmaceuticals must remain equivalent throughout their lifecycle.<sup id=\"cite_ref-pmid21478841_15-0\" class=\"reference\"><a href=\"#cite_note-pmid21478841-15\">&#91;15&#93;</a></sup> <sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> Process variations are monitored by modern analytical tools (e.g., <a href=\"/wiki/Liquid_chromatography\" class=\"mw-redirect\" title=\"Liquid chromatography\">liquid chromatography</a>, <a href=\"/wiki/Immunoassays\" class=\"mw-redirect\" title=\"Immunoassays\">immunoassays</a>, <a href=\"/wiki/Mass_spectrometry\" title=\"Mass spectrometry\">mass spectrometry</a>, etc.) and describe a unique design space for each biologic.\n</p><p>Thus, biosimilars require a different regulatory framework compared to small-molecule generics. Legislation in the 21st century has addressed this by recognizing an intermediate ground of testing for biosimilars. The filing pathway requires more testing than for small-molecule generics, but less testing than for registering completely new therapeutics.<sup id=\"cite_ref-biosimilars2012_17-0\" class=\"reference\"><a href=\"#cite_note-biosimilars2012-17\">&#91;17&#93;</a></sup>\n</p><p>In 2003, the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> introduced an adapted pathway for biosimilars, termed <a href=\"/wiki/Biosimilar\" title=\"Biosimilar\"><i>similar biological medicinal products</i></a>. This pathway is based on a thorough demonstration of \"comparability\" of the \"similar\" product to an existing approved product.<sup id=\"cite_ref-EMA1_18-0\" class=\"reference\"><a href=\"#cite_note-EMA1-18\">&#91;18&#93;</a></sup> Within the United States, the <a href=\"/wiki/Patient_Protection_and_Affordable_Care_Act\" title=\"Patient Protection and Affordable Care Act\">Patient Protection and Affordable Care Act</a> of 2010 created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product.<sup id=\"cite_ref-biosimilars2012_17-1\" class=\"reference\"><a href=\"#cite_note-biosimilars2012-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-urlwww.gpo.gov_19-0\" class=\"reference\"><a href=\"#cite_note-urlwww.gpo.gov-19\">&#91;19&#93;</a></sup> A major hope linked to the introduction of biosimilars is a reduction of costs to the patients and the healthcare system.<sup id=\"cite_ref-biosimilars_14-1\" class=\"reference\"><a href=\"#cite_note-biosimilars-14\">&#91;14&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Commercialization\">Commercialization</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=7\" title=\"Edit section: Commercialization\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>When a new biopharmaceutical is developed, the company will typically apply for a <a href=\"/wiki/Patent\" title=\"Patent\">patent</a>, which is a grant for exclusive manufacturing rights. This is the primary means by which the developer of the drug can recover the investment cost for development of the biopharmaceutical. The <a href=\"/wiki/United_States_patent_law\" title=\"United States patent law\">patent laws</a> in the <a href=\"/wiki/United_States\" title=\"United States\">United States</a> and <a href=\"/wiki/Europe\" title=\"Europe\">Europe</a> differ somewhat on the requirements for a patent, with the European requirements are perceived as more difficult to satisfy. The total number of patents granted for biopharmaceuticals has risen significantly since the 1970s. In 1978 the total patents granted was 30. This had climbed to 15,600 in 1995, and by 2001 there were 34,527 patent applications.<sup id=\"cite_ref-scientific_thomson_2006_20-0\" class=\"reference\"><a href=\"#cite_note-scientific_thomson_2006-20\">&#91;20&#93;</a></sup> In 2012 the US had the highest IP (Intellectual Property) generation within the biopharmaceutical industry, generating 37 percent of the total number of granted patents worldwide, however, there is still a large margin for growth and innovation within the industry. Revisions to the current IP system to ensure greater reliability for R&amp;D (research and development) investments is a prominent topic of debate in the US as well.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> Blood products and other human derived biologics like breast milk, have highly regulated or very hard to access markets, therefore, customers generally face a supply shortage for these products due to their nature and often institutions housing these biologics, designated as 'banks', cannot distribute their product to customers effectively.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> Conversely, banks for reproductive cells are much more widespread and available due to the ease of which <a href=\"/wiki/Spermatozoon\" title=\"Spermatozoon\">spermatozoa</a> and <a href=\"/wiki/Egg_cell\" title=\"Egg cell\">egg cells</a> are able to be used for fertility treatment.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Large-scale_production\">Large-scale production</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=8\" title=\"Edit section: Large-scale production\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Biopharmaceuticals may be produced from microbial cells (e.g., <a href=\"/wiki/Escherichia_coli\" title=\"Escherichia coli\">recombinant <i>E. coli</i></a> or yeast cultures), mammalian cell lines (see <a href=\"/wiki/Cell_culture\" title=\"Cell culture\">cell culture</a>) and plant cell cultures (see <a href=\"/wiki/Plant_tissue_culture\" title=\"Plant tissue culture\">plant tissue culture</a>) and <a href=\"/wiki/Moss\" title=\"Moss\">moss</a> plants in <a href=\"/wiki/Bioreactor\" title=\"Bioreactor\">bioreactors</a> of various configurations, including <a href=\"/wiki/Photo-bioreactors\" class=\"mw-redirect\" title=\"Photo-bioreactors\">photo-bioreactors</a>.<sup id=\"cite_ref-pmid17701058_24-0\" class=\"reference\"><a href=\"#cite_note-pmid17701058-24\">&#91;24&#93;</a></sup> Important issues of concern are cost of production (low-volume, high-purity products are desirable) and microbial contamination (by <a href=\"/wiki/Bacteria\" title=\"Bacteria\">bacteria</a>, <a href=\"/wiki/Virus\" title=\"Virus\">viruses</a>, <a href=\"/wiki/Mycoplasma\" title=\"Mycoplasma\">mycoplasma</a>). Alternative platforms of production which are being tested include whole plants (<a href=\"/wiki/Plant-made_pharmaceuticals\" class=\"mw-redirect\" title=\"Plant-made pharmaceuticals\">plant-made pharmaceuticals</a>).\n</p>\n<h3><span class=\"mw-headline\" id=\"Transgenics\">Transgenics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=9\" title=\"Edit section: Transgenics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Pharming_(genetics)\" title=\"Pharming (genetics)\">Pharming (genetics)</a></div>\n<p>A potentially controversial method of producing biopharmaceuticals involves <a href=\"/wiki/Transgenic\" class=\"mw-redirect\" title=\"Transgenic\">transgenic</a> organisms, particularly plants and animals that have been <a href=\"/wiki/Genetically_modified\" class=\"mw-redirect\" title=\"Genetically modified\">genetically modified</a> to produce drugs. This production is a significant risk for the investor, due to production failure or scrutiny from regulatory bodies based on perceived risks and ethical issues. Biopharmaceutical crops also represent a risk of cross-contamination with non-engineered crops, or crops engineered for non-medical purposes.\n</p><p>One potential approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk, blood, or urine. Once an animal is produced, typically using the <a href=\"/wiki/Microinjection#Pronuclear_injection\" title=\"Microinjection\">pronuclear microinjection</a> method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome.<sup id=\"cite_ref-pmid11017040_25-0\" class=\"reference\"><a href=\"#cite_note-pmid11017040-25\">&#91;25&#93;</a></sup> The first such drug manufactured from the milk of a genetically modified <a href=\"/wiki/Goat\" title=\"Goat\">goat</a> was <a href=\"/wiki/ATryn\" title=\"ATryn\">ATryn</a>, but marketing permission was blocked by the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> in February 2006.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> This decision was reversed in June 2006 and approval was given August 2006.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Regulation\">Regulation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=10\" title=\"Edit section: Regulation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"European_Union\">European Union</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=11\" title=\"Edit section: European Union\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In the <a href=\"/wiki/European_Union\" title=\"European Union\">European Union</a>, a <b>biological medicinal product</b><sup id=\"cite_ref-urlec.europa.eu_28-0\" class=\"reference\"><a href=\"#cite_note-urlec.europa.eu-28\">&#91;28&#93;</a></sup> is one of the active substance(s) produced from or extracted from a biological (living) system, and requires, in addition to physico-chemical testing, biological testing for full characterisation. The characterisation of a biological medicinal product is a combination of testing the active substance and the final medicinal product together with the production process and its control. For example:\n</p>\n<ul><li>Production process \u2013 it can be derived from biotechnology or from other technologies. It may be prepared using more conventional techniques as is the case for blood or <a href=\"/wiki/Blood_plasma\" title=\"Blood plasma\">plasma</a>-derived products and a number of vaccines.</li>\n<li>Active substance \u2013 consisting of entire microorganisms, mammalian cells, nucleic acids, proteinaceous, or <a href=\"/wiki/Polysaccharide\" title=\"Polysaccharide\">polysaccharide</a> components originating from a microbial, animal, human, or plant source.</li>\n<li>Mode of action \u2013 therapeutic and immunological medicinal products, <a href=\"/wiki/Horizontal_gene_transfer\" title=\"Horizontal gene transfer\">gene transfer</a> materials, or <a href=\"/wiki/Cell_therapy\" title=\"Cell therapy\">cell therapy</a> materials.</li></ul>\n<h3><span class=\"mw-headline\" id=\"United_States\">United States</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=12\" title=\"Edit section: United States\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In the <a href=\"/wiki/United_States\" title=\"United States\">United States</a>, biologics are licensed through the biologics license application (BLA), then submitted to and regulated by the FDA's <a href=\"/wiki/Center_for_Biologics_Evaluation_and_Research\" title=\"Center for Biologics Evaluation and Research\">Center for Biologics Evaluation and Research</a> (CBER) whereas drugs are regulated by the <a href=\"/wiki/Center_for_Drug_Evaluation_and_Research\" title=\"Center for Drug Evaluation and Research\">Center for Drug Evaluation and Research</a>. Approval may require several years of <a href=\"/wiki/Clinical_trials\" class=\"mw-redirect\" title=\"Clinical trials\">clinical trials</a>, including trials with human volunteers. Even after the drug is released, it will still be monitored for performance and safety risks. The manufacture process must satisfy the FDA's \"Good Manufacturing Practices\", which are typically manufactured in a <a href=\"/wiki/Clean_room\" class=\"mw-redirect\" title=\"Clean room\">clean room</a> environment with strict limits on the amount of airborne particles and other microbial contaminants that may alter the efficacy of the drug.<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=13\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Antibody-drug_conjugate\" title=\"Antibody-drug conjugate\">Antibody-drug conjugate</a></li>\n<li><a href=\"/wiki/Genetic_engineering\" title=\"Genetic engineering\">Genetic engineering</a></li>\n<li><a href=\"/wiki/List_of_recombinant_proteins\" title=\"List of recombinant proteins\">List of recombinant proteins</a></li>\n<li><a href=\"/wiki/List_of_pharmaceutical_companies\" title=\"List of pharmaceutical companies\">List of pharmaceutical companies</a></li>\n<li><a href=\"/wiki/Nanobiopharmaceutics\" class=\"mw-redirect\" title=\"Nanobiopharmaceutics\">Nanobiopharmaceutics</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=14\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 33em; -webkit-column-width: 33em; column-width: 33em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.oxforddictionaries.com/us/definition/english/biological\">Definition of \"biological\" at Oxford Dictionaries</a></span>\n</li>\n<li id=\"cite_note-pmid18612293-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid18612293_2-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rader RA (July 2008). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nature.com/nbt/journal/v26/n7/box/nbt0708-743_BX3.html\">\"(Re)defining biopharmaceutical\"</a>. <i>Nature Biotechnology</i>. <b>26</b> (7): 743\u201351. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nbt0708-743\">10.1038/nbt0708-743</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18612293\">18612293</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Biotechnology&amp;rft.atitle=%28Re%29defining+biopharmaceutical&amp;rft.volume=26&amp;rft.issue=7&amp;rft.pages=743-51&amp;rft.date=2008-07&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt0708-743&amp;rft_id=info%3Apmid%2F18612293&amp;rft.aulast=Rader&amp;rft.aufirst=RA&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnbt%2Fjournal%2Fv26%2Fn7%2Fbox%2Fnbt0708-743_BX3.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm\">\"Drugs@FDA Glossary of Terms\"</a>. <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a>. 2 Feb 2012<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 April</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Drugs%40FDA+Glossary+of+Terms&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=2012-02-02&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FAboutFDA%2FTransparency%2FBasics%2Fucm194516.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Walsh G (2003). <i>Biopharmaceuticals: Biochemistry and Biotechnology, Second Edition</i>. John Wiley &amp; Sons Ltd. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-470-84326-0\" title=\"Special:BookSources/978-0-470-84326-0\">978-0-470-84326-0</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Biopharmaceuticals%3A+Biochemistry+and+Biotechnology%2C+Second+Edition&amp;rft.pub=John+Wiley+%26+Sons+Ltd&amp;rft.date=2003&amp;rft.isbn=978-0-470-84326-0&amp;rft.aulast=Walsh&amp;rft.aufirst=Gary&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ncbi_2013-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-ncbi_2013_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND (September 2013). \"Health plan utilization and costs of specialty drugs within 4 chronic conditions\". <i>Journal of Managed Care Pharmacy</i>. <b>19</b> (7): 542\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.18553/jmcp.2013.19.7.542\">10.18553/jmcp.2013.19.7.542</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23964615\">23964615</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Managed+Care+Pharmacy&amp;rft.atitle=Health+plan+utilization+and+costs+of+specialty+drugs+within+4+chronic+conditions&amp;rft.volume=19&amp;rft.issue=7&amp;rft.pages=542-8&amp;rft.date=2013-09&amp;rft_id=info%3Adoi%2F10.18553%2Fjmcp.2013.19.7.542&amp;rft_id=info%3Apmid%2F23964615&amp;rft.aulast=Gleason&amp;rft.aufirst=PP&amp;rft.au=Alexander%2C+GC&amp;rft.au=Starner%2C+CI&amp;rft.au=Ritter%2C+ST&amp;rft.au=Van+Houten%2C+HK&amp;rft.au=Gunderson%2C+BW&amp;rft.au=Shah%2C+ND&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-nytimes.com_2015_07_16-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-nytimes.com_2015_07_16_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Thomas, Kate; Pollack, Andrew (15 July 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2015/07/16/business/specialty-pharmacies-proliferate-along-with-questions.html\">\"Specialty Pharmacies Proliferate, Along With Questions\"</a>. Sinking Spring, Pa.: New York Times<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">5 October</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Specialty+Pharmacies+Proliferate%2C+Along+With+Questions&amp;rft.place=Sinking+Spring%2C+Pa.&amp;rft.pub=New+York+Times&amp;rft.date=2015-07-15&amp;rft.au=Thomas%2C+Kate&amp;rft.au=Pollack%2C+Andrew&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F07%2F16%2Fbusiness%2Fspecialty-pharmacies-proliferate-along-with-questions.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-UofW-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-UofW_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Murphy CO. <a rel=\"nofollow\" class=\"external text\" href=\"https://courses.washington.edu/pharm542/Week4/slidesSpecialty%20Pharmacy%20%20Managed%20Care%20Strategies%200410.pdf\">\"Specialty Pharmacy Managed Care Strategies\"</a> <span style=\"font-size:85%;\">(PDF)</span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">24 September</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Specialty+Pharmacy+Managed+Care+Strategies&amp;rft.aulast=Murphy&amp;rft.aufirst=Chad+O.&amp;rft_id=https%3A%2F%2Fcourses.washington.edu%2Fpharm542%2FWeek4%2FslidesSpecialty%2520Pharmacy%2520%2520Managed%2520Care%2520Strategies%25200410.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-EMA_CAT-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-EMA_CAT_8-0\">^</a></b></span> <span class=\"reference-text\"><cite id=\"CITEREFEuropean_Medicines_Agency\" class=\"citation\"><a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a>, \"tooltip definition of advanced therapy medicinal products\", <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000266.jsp\"><i>Committee for Advanced Therapies (CAT)</i></a><span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">2017-05-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=tooltip+definition+of+advanced+therapy+medicinal+products&amp;rft.btitle=Committee+for+Advanced+Therapies+%28CAT%29&amp;rft.au=European+Medicines+Agency&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fabout_us%2Fgeneral%2Fgeneral_content_000266.jsp&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-EMA_ATMPs-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-EMA_ATMPs_9-0\">^</a></b></span> <span class=\"reference-text\"><cite id=\"CITEREFEuropean_Medicines_Agency\" class=\"citation\"><a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a>, <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000294.jsp\"><i>Advanced therapy medicinal products</i></a><span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">2017-05-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Advanced+therapy+medicinal+products&amp;rft.au=European+Medicines+Agency&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fregulation%2Fgeneral%2Fgeneral_content_000294.jsp&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-FDA_FAQ-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-FDA_FAQ_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Center for Biologics Evaluation and Research (2010-04-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm\">\"What is a biological product?\"</a>. U.S. Food and Drug Administration<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2014-02-09</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=What+is+a+biological+product%3F&amp;rft.pub=U.S.+Food+and+Drug+Administration&amp;rft.date=2010-04-01&amp;rft.au=Center+for+Biologics+Evaluation+and+Research&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FAboutFDA%2FTransparency%2FBasics%2Fucm194516.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid18958946-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid18958946_11-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">United States Food and Drug Administration (August 2008). <a rel=\"nofollow\" class=\"external text\" href=\"http://edocket.access.gpo.gov/2008/pdf/E8-19572.pdf\">\"Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Federal Register</i>. <b>73</b> (164): 49603\u201310. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18958946\">18958946</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Federal+Register&amp;rft.atitle=Supplemental+applications+proposing+labeling+changes+for+approved+drugs%2C+biologics%2C+and+medical+devices.+Final+rule&amp;rft.volume=73&amp;rft.issue=164&amp;rft.pages=49603-10&amp;rft.date=2008-08&amp;rft_id=info%3Apmid%2F18958946&amp;rft.au=United+States+Food+and+Drug+Administration&amp;rft_id=http%3A%2F%2Fedocket.access.gpo.gov%2F2008%2Fpdf%2FE8-19572.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kerr LD (2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.musculoskeletalnetwork.com/arthritis/content/article/1145622/1562177\">\"The use of biologic agents in the geriatric population\"</a>. <i>J Musculoskel Med</i>. <b>27</b>: 175\u2013180.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Musculoskel+Med&amp;rft.atitle=The+use+of+biologic+agents+in+the+geriatric+population&amp;rft.volume=27&amp;rft.pages=175-180&amp;rft.date=2010&amp;rft.aulast=Kerr&amp;rft.aufirst=LD&amp;rft_id=http%3A%2F%2Fwww.musculoskeletalnetwork.com%2Farthritis%2Fcontent%2Farticle%2F1145622%2F1562177&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">BriskFox Financial. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.briskfox.com/open/years/2009_q1/do_v_c44751.php\">\"Biopharmaceutical sector sees rising R&amp;D despite credit crunch, finds analysis\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2009-03-11</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Biopharmaceutical+sector+sees+rising+R%26D+despite+credit+crunch%2C+finds+analysis&amp;rft.au=BriskFox+Financial&amp;rft_id=http%3A%2F%2Fwww.briskfox.com%2Fopen%2Fyears%2F2009_q1%2Fdo_v_c44751.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-biosimilars-14\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-biosimilars_14-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-biosimilars_14-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Calo-Fern\u00e1ndez B, Mart\u00ednez-Hurtado JL (December 2012). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668\">\"Biosimilars: company strategies to capture value from the biologics market\"</a>. <i>Pharmaceuticals</i>. <b>5</b> (12): 1393\u2013408. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3390/ph5121393\">10.3390/ph5121393</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668\">3816668</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24281342\">24281342</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmaceuticals&amp;rft.atitle=Biosimilars%3A+company+strategies+to+capture+value+from+the+biologics+market&amp;rft.volume=5&amp;rft.issue=12&amp;rft.pages=1393-408&amp;rft.date=2012-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3816668&amp;rft_id=info%3Apmid%2F24281342&amp;rft_id=info%3Adoi%2F10.3390%2Fph5121393&amp;rft.aulast=Calo-Fern%C3%A1ndez&amp;rft.aufirst=B&amp;rft.au=Mart%C3%ADnez-Hurtado%2C+JL&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3816668&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid21478841-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid21478841_15-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R (April 2011). \"Acceptable changes in quality attributes of glycosylated biopharmaceuticals\". <i>Nature Biotechnology</i>. <b>29</b> (4): 310\u20132. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nbt.1839\">10.1038/nbt.1839</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21478841\">21478841</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Biotechnology&amp;rft.atitle=Acceptable+changes+in+quality+attributes+of+glycosylated+biopharmaceuticals&amp;rft.volume=29&amp;rft.issue=4&amp;rft.pages=310-2&amp;rft.date=2011-04&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt.1839&amp;rft_id=info%3Apmid%2F21478841&amp;rft.aulast=Schiestl&amp;rft.aufirst=M&amp;rft.au=Stangler%2C+T&amp;rft.au=Torella%2C+C&amp;rft.au=Cepeljnik%2C+T&amp;rft.au=Toll%2C+H&amp;rft.au=Grau%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M (April 2018). \"Maintaining consistent quality and clinical performance of biopharmaceuticals\". <i>Expert Opinion on Biological Therapy</i>. <b>18</b> (4): 369\u2013379. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1080/14712598.2018.1421169\">10.1080/14712598.2018.1421169</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/29285958\">29285958</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Opinion+on+Biological+Therapy&amp;rft.atitle=Maintaining+consistent+quality+and+clinical+performance+of+biopharmaceuticals&amp;rft.volume=18&amp;rft.issue=4&amp;rft.pages=369-379&amp;rft.date=2018-04&amp;rft_id=info%3Adoi%2F10.1080%2F14712598.2018.1421169&amp;rft_id=info%3Apmid%2F29285958&amp;rft.aulast=Lamanna&amp;rft.aufirst=WC&amp;rft.au=Holzmann%2C+J&amp;rft.au=Cohen%2C+HP&amp;rft.au=Guo%2C+X&amp;rft.au=Schweigler%2C+M&amp;rft.au=Stangler%2C+T&amp;rft.au=Seidl%2C+A&amp;rft.au=Schiestl%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-biosimilars2012-17\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-biosimilars2012_17-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-biosimilars2012_17-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Nick C (2012). <a rel=\"nofollow\" class=\"external text\" href=\"http://adisonline.com/pharmaceuticalmedicine/Abstract/2012/26030/The_US_Biosimilars_Act__Challenges_Facing.1.aspx\">\"The US Biosimilars Act: Challenges Facing Regulatory Approval\"</a>. <i>Pharm Med</i>. <b>26</b> (3): 145\u2013152. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/bf03262388\">10.1007/bf03262388</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharm+Med&amp;rft.atitle=The+US+Biosimilars+Act%3A+Challenges+Facing+Regulatory+Approval&amp;rft.volume=26&amp;rft.issue=3&amp;rft.pages=145-152&amp;rft.date=2012&amp;rft_id=info%3Adoi%2F10.1007%2Fbf03262388&amp;rft.aulast=Nick&amp;rft.aufirst=C&amp;rft_id=http%3A%2F%2Fadisonline.com%2Fpharmaceuticalmedicine%2FAbstract%2F2012%2F26030%2FThe_US_Biosimilars_Act&#95;_Challenges_Facing.1.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-EMA1-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-EMA1_18-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">EMA (2008-10-30). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf\">\"Questions and answers on biosimilar medicines (similar biological medicinal products)\"</a> <span style=\"font-size:85%;\">(PDF)</span>. European Medicines Agency<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2014-10-11</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Questions+and+answers+on+biosimilar+medicines+%28similar+biological+medicinal+products%29&amp;rft.pub=European+Medicines+Agency&amp;rft.date=2008-10-30&amp;rft.au=EMA&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FMedicine_QA%2F2009%2F12%2FWC500020062.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-urlwww.gpo.gov-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-urlwww.gpo.gov_19-0\">^</a></b></span> <span class=\"reference-text\">75 <a href=\"/wiki/Federal_Register\" title=\"Federal Register\">FR</a> <a rel=\"nofollow\" class=\"external text\" href=\"//www.federalregister.gov/citation/75-FR-61497\">61497</a>; <cite class=\"citation web\">United States Food and Drug Administration (2010-10-05). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.gpo.gov/fdsys/pkg/FR-2010-10-05/pdf/2010-24853.pdf\">\"Approval Pathway for Biosimilar and Interchangeable Biological Products\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Public Hearing; Request for Comments</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Public+Hearing%3B+Request+for+Comments&amp;rft.atitle=Approval+Pathway+for+Biosimilar+and+Interchangeable+Biological+Products&amp;rft.date=2010-10-05&amp;rft.au=United+States+Food+and+Drug+Administration&amp;rft_id=http%3A%2F%2Fwww.gpo.gov%2Ffdsys%2Fpkg%2FFR-2010-10-05%2Fpdf%2F2010-24853.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-scientific_thomson_2006-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-scientific_thomson_2006_20-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Foster, Luke. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20060316164416/http://scientific.thomson.com/free/ipmatters/pii/8180019/\">\"Patenting in the Biopharmaceutical Industry&#8212;comparing the US with Europe\"</a>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://scientific.thomson.com/free/ipmatters/pii/8180019/\">the original</a> on 2006-03-16<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-06-23</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Patenting+in+the+Biopharmaceutical+Industry%26mdash%3Bcomparing+the+US+with+Europe&amp;rft.aulast=Foster&amp;rft.aufirst=Luke&amp;rft_id=http%3A%2F%2Fscientific.thomson.com%2Ffree%2Fipmatters%2Fpii%2F8180019%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.phrma.org/press-release/new-report-reveals-growth-trajectories-and-top-policy-factors-affecting-biopharmaceutical-innovation-and-growth\">\"Growth and Policies Behind Biopharmaceutical Innovation\"</a>. <i>phrma.org</i>. PhRMA<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">11 April</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=phrma.org&amp;rft.atitle=Growth+and+Policies+Behind+Biopharmaceutical+Innovation&amp;rft_id=https%3A%2F%2Fwww.phrma.org%2Fpress-release%2Fnew-report-reveals-growth-trajectories-and-top-policy-factors-affecting-biopharmaceutical-innovation-and-growth&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Carlyle, Erin. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.forbes.com/sites/erincarlyle/2012/06/27/blood-money-the-guys-who-trade-your-blood-for-profit/#2ec937e46884\">\"The Guys Who Trade Your Blood For Profit\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-09-29</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+Guys+Who+Trade+Your+Blood+For+Profit&amp;rft.aulast=Carlyle&amp;rft.aufirst=Erin&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Ferincarlyle%2F2012%2F06%2F27%2Fblood-money-the-guys-who-trade-your-blood-for-profit%2F%232ec937e46884&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.spermdonorsaustralia.com.au/\">\"Sperm Donors Australia | Donate Sperm\"</a>. <i>www.spermdonorsaustralia.com.au</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-09-29</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.spermdonorsaustralia.com.au&amp;rft.atitle=Sperm+Donors+Australia+%7C+Donate+Sperm&amp;rft_id=http%3A%2F%2Fwww.spermdonorsaustralia.com.au%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17701058-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17701058_24-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Decker EL, Reski R (January 2008). \"Current achievements in the production of complex biopharmaceuticals with moss bioreactors\". <i>Bioprocess and Biosystems Engineering</i>. <b>31</b> (1): 3\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s00449-007-0151-y\">10.1007/s00449-007-0151-y</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17701058\">17701058</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bioprocess+and+Biosystems+Engineering&amp;rft.atitle=Current+achievements+in+the+production+of+complex+biopharmaceuticals+with+moss+bioreactors&amp;rft.volume=31&amp;rft.issue=1&amp;rft.pages=3-9&amp;rft.date=2008-01&amp;rft_id=info%3Adoi%2F10.1007%2Fs00449-007-0151-y&amp;rft_id=info%3Apmid%2F17701058&amp;rft.aulast=Decker&amp;rft.aufirst=EL&amp;rft.au=Reski%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid11017040-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid11017040_25-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Dove A (October 2000). \"Milking the genome for profit\". <i>Nature Biotechnology</i>. <b>18</b> (10): 1045\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/80231\">10.1038/80231</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11017040\">11017040</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Biotechnology&amp;rft.atitle=Milking+the+genome+for+profit&amp;rft.volume=18&amp;rft.issue=10&amp;rft.pages=1045-8&amp;rft.date=2000-10&amp;rft_id=info%3Adoi%2F10.1038%2F80231&amp;rft_id=info%3Apmid%2F11017040&amp;rft.aulast=Dove&amp;rft.aufirst=A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Phillip B. C. Jones. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.isb.vt.edu/articles/apr0603.htm\">\"European Regulators Curdle Plans for Goat Milk Human Antithrombin\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-06-23</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=European+Regulators+Curdle+Plans+for+Goat+Milk+Human+Antithrombin&amp;rft.au=Phillip+B.+C.+Jones&amp;rft_id=http%3A%2F%2Fwww.isb.vt.edu%2Farticles%2Fapr0603.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://news.bbc.co.uk/1/hi/sci/tech/5041298.stm\">\"Go-ahead for 'pharmed' goat drug\"</a>. <i>BBC News</i>. 2006-06-02<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2006-10-25</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BBC+News&amp;rft.atitle=Go-ahead+for+%27pharmed%27+goat+drug&amp;rft.date=2006-06-02&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fsci%2Ftech%2F5041298.stm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-urlec.europa.eu-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-urlec.europa.eu_28-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">The Commission of the European Communities (2003-06-25). <a rel=\"nofollow\" class=\"external text\" href=\"http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_63/dir_2003_63_en.pdf\">\"Commission Directive 2003/63/EC amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Official Journal of the European Union</i>. p.&#160;L 159/62.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Official+Journal+of+the+European+Union&amp;rft.atitle=Commission+Directive+2003%2F63%2FEC+amending+Directive+2001%2F83%2FEC+of+the+European+Parliament+and+of+the+Council+on+the+Community+code+relating+to+medicinal+products+for+human+use&amp;rft.pages=L+159%2F62&amp;rft.date=2003-06-25&amp;rft.au=The+Commission+of+the+European+Communities&amp;rft_id=http%3A%2F%2Fec.europa.eu%2Fhealth%2Ffiles%2Feudralex%2Fvol-1%2Fdir_2003_63%2Fdir_2003_63_en.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Kingham R, Klasa G, Carver K (2014). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.cov.com/-/media/files/corporate/publications/2013/10/chapter4_key_regulatory_guidlines_for_the_development_of_biologics_in_the_united_states_and_europe.pdf\"><i>Key Regulatory Guidelines for the Development of Biologics in the United States and Europe</i></a> <span style=\"font-size:85%;\">(PDF)</span>. John Wiley &amp; Sons, Inc. pp.&#160;75\u201388<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">11 April</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Key+Regulatory+Guidelines+for+the+Development+of+Biologics+in+the+United+States+and+Europe&amp;rft.pages=75-88&amp;rft.pub=John+Wiley+%26+Sons%2C+Inc.&amp;rft.date=2014&amp;rft.aulast=Kingham&amp;rft.aufirst=Richard&amp;rft.au=Klasa%2C+Gabriela&amp;rft.au=Carver%2C+Krista&amp;rft_id=https%3A%2F%2Fwww.cov.com%2F-%2Fmedia%2Ffiles%2Fcorporate%2Fpublications%2F2013%2F10%2Fchapter4_key_regulatory_guidlines_for_the_development_of_biologics_in_the_united_states_and_europe.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Biopharmaceutical&amp;action=edit&amp;section=15\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"https://meshb.nlm.nih.gov/record/ui?name=Biological%20Products\">Biological+Products</a> at the US National Library of Medicine <a href=\"/wiki/Medical_Subject_Headings\" title=\"Medical Subject Headings\">Medical Subject Headings</a> (MeSH)</li>\n<li><cite class=\"citation web\">Debbie Strickland (2007). <a rel=\"nofollow\" class=\"external text\" href=\"http://bio.org/speeches/pubs/er/BiotechGuide.pdf\">\"Guide to Biotechnology\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Biotechnology Industry Organization (BIO)<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-12-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Guide+to+Biotechnology&amp;rft.pub=Biotechnology+Industry+Organization+%28BIO%29&amp;rft.date=2007&amp;rft.au=Debbie+Strickland&amp;rft_id=http%3A%2F%2Fbio.org%2Fspeeches%2Fpubs%2Fer%2FBiotechGuide.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation web\">Timothy B. Coan; Ron Ellis (2001-06-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cptech.org/ip/health/biotech/genbio062001.pdf\">\"Report for USA Specialty Pharmaceuticals: Generic Biologics: The Next Frontier\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Consumer Project on Technology<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-12-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Report+for+USA+Specialty+Pharmaceuticals%3A+Generic+Biologics%3A+The+Next+Frontier&amp;rft.pub=Consumer+Project+on+Technology&amp;rft.date=2001-06-01&amp;rft.au=Timothy+B.+Coan&amp;rft.au=Ron+Ellis&amp;rft_id=http%3A%2F%2Fwww.cptech.org%2Fip%2Fhealth%2Fbiotech%2Fgenbio062001.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.psoriasis.org/treatment/psoriasis/biologics/about.php\">\"About biologics\"</a>. National Psoriasis Foundation. 2006-11-01<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-12-17</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=About+biologics&amp;rft.pub=National+Psoriasis+Foundation&amp;rft.date=2006-11-01&amp;rft_id=http%3A%2F%2Fwww.psoriasis.org%2Ftreatment%2Fpsoriasis%2Fbiologics%2Fabout.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ABiopharmaceutical\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw2229\nCached time: 20180915015802\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.372 seconds\nReal time usage: 0.422 seconds\nPreprocessor visited node count: 1435/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 57164/2097152 bytes\nTemplate argument size: 167/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 35956/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.173/10.000 seconds\nLua memory usage: 3.49 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  307.739      1 -total\n 71.83%  221.039      1 Template:Reflist\n 28.55%   87.857     10 Template:Cite_journal\n 26.05%   80.177     17 Template:Cite_web\n  9.71%   29.884      1 Template:See_also\n  4.33%   13.317      2 Template:Citation\n  3.52%   10.829      2 Template:Cite_book\n  3.42%   10.527      3 Template:Main_article\n  2.89%    8.893      1 Template:MeshName\n  0.76%    2.328      1 Template:Federal_Register\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:2654847-0!canonical and timestamp 20180915015802 and revision id 851520426\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D9%85%D8%B3%D8%AA%D8%AD%D8%B6%D8%B1%D8%A7%D8%AA_%D8%AF%D9%88%D8%A7%D8%A6%D9%8A%D8%A9_%D8%AD%D9%8A%D9%88%D9%8A%D8%A9","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0645\u0633\u062a\u062d\u0636\u0631\u0627\u062a \u062f\u0648\u0627\u0626\u064a\u0629 \u062d\u064a\u0648\u064a\u0629"},{"lang":"ca","url":"https://ca.wikipedia.org/wiki/Medicament_biol%C3%B2gic","langname":"Catalan","autonym":"catal\u00e0","*":"Medicament biol\u00f2gic"},{"lang":"de","url":"https://de.wikipedia.org/wiki/Biopharmazeutikum","langname":"German","autonym":"Deutsch","*":"Biopharmazeutikum"},{"lang":"es","url":"https://es.wikipedia.org/wiki/Biofarmac%C3%A9utica","langname":"Spanish","autonym":"espa\u00f1ol","*":"Biofarmac\u00e9utica"},{"lang":"eo","url":"https://eo.wikipedia.org/wiki/Biofarmacio","langname":"Esperanto","autonym":"Esperanto","*":"Biofarmacio"},{"lang":"eu","url":"https://eu.wikipedia.org/wiki/Sendagai_biologiko","langname":"Basque","autonym":"euskara","*":"Sendagai biologiko"},{"lang":"fa","url":"https://fa.wikipedia.org/wiki/%D8%B2%DB%8C%D8%B3%D8%AA%E2%80%8C%D8%AF%D8%A7%D8%B1%D9%88","langname":"Persian","autonym":"\u0641\u0627\u0631\u0633\u06cc","*":"\u0632\u06cc\u0633\u062a\u200c\u062f\u0627\u0631\u0648"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/M%C3%A9dicament_biologique","langname":"French","autonym":"fran\u00e7ais","*":"M\u00e9dicament biologique"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Farmaco_biologico","langname":"Italian","autonym":"italiano","*":"Farmaco biologico"},{"lang":"kk","url":"https://kk.wikipedia.org/wiki/%D0%91%D0%B8%D0%BE%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D1%82%D0%B0%D1%80","langname":"Kazakh","autonym":"\u049b\u0430\u0437\u0430\u049b\u0448\u0430","*":"\u0411\u0438\u043e\u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0442\u0430\u0440"},{"lang":"lmo","url":"https://lmo.wikipedia.org/wiki/Biofarmaceuteg","langname":"Lombard","autonym":"lumbaart","*":"Biofarmaceuteg"},{"lang":"hu","url":"https://hu.wikipedia.org/wiki/Biol%C3%B3giai_gy%C3%B3gyszer","langname":"Hungarian","autonym":"magyar","*":"Biol\u00f3giai gy\u00f3gyszer"},{"lang":"nl","url":"https://nl.wikipedia.org/wiki/Biological","langname":"Dutch","autonym":"Nederlands","*":"Biological"},{"lang":"ja","url":"https://ja.wikipedia.org/wiki/%E3%83%90%E3%82%A4%E3%82%AA%E5%8C%BB%E8%96%AC%E5%93%81","langname":"Japanese","autonym":"\u65e5\u672c\u8a9e","*":"\u30d0\u30a4\u30aa\u533b\u85ac\u54c1"},{"lang":"uz","url":"https://uz.wikipedia.org/wiki/Biologik_preparatlar","langname":"Uzbek","autonym":"o\u02bbzbekcha/\u045e\u0437\u0431\u0435\u043a\u0447\u0430","*":"Biologik preparatlar"},{"lang":"pl","url":"https://pl.wikipedia.org/wiki/Biofarmaceutyki","langname":"Polish","autonym":"polski","*":"Biofarmaceutyki"},{"lang":"pt","url":"https://pt.wikipedia.org/wiki/Biof%C3%A1rmaco","langname":"Portuguese","autonym":"portugu\u00eas","*":"Biof\u00e1rmaco"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/%D0%91%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D1%8B","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"\u0411\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b"},{"lang":"sr","url":"https://sr.wikipedia.org/wiki/%D0%91%D0%B8%D0%BE%D0%BB%D0%BE%D1%88%D0%BA%D0%B8_%D0%BB%D0%B5%D0%BA","langname":"Serbian","autonym":"\u0441\u0440\u043f\u0441\u043a\u0438 / srpski","*":"\u0411\u0438\u043e\u043b\u043e\u0448\u043a\u0438 \u043b\u0435\u043a"},{"lang":"sv","url":"https://sv.wikipedia.org/wiki/Biologiska_l%C3%A4kemedel","langname":"Swedish","autonym":"svenska","*":"Biologiska l\u00e4kemedel"},{"lang":"zh","url":"https://zh.wikipedia.org/wiki/%E7%94%9F%E7%89%A9%E6%B2%BB%E7%99%82","langname":"Chinese","autonym":"\u4e2d\u6587","*":"\u751f\u7269\u6cbb\u7642"}],"categories":[{"sortkey":"","*":"Biotechnology"},{"sortkey":"","*":"Biotechnology_products"},{"sortkey":" ","*":"Biopharmaceuticals"},{"sortkey":"","*":"Pharmaceutical_industry"},{"sortkey":"","*":"Life_sciences_industry"},{"sortkey":"","*":"Specialty_drugs"},{"sortkey":"","*":"Pharmacy"}],"links":[{"ns":0,"exists":"","*":"ATryn"},{"ns":0,"exists":"","*":"Abatacept"},{"ns":0,"exists":"","*":"Active ingredients"},{"ns":0,"exists":"","*":"Adalimumab"},{"ns":0,"exists":"","*":"Alefacept"},{"ns":0,"exists":"","*":"Allergenic"},{"ns":0,"exists":"","*":"Anemia"},{"ns":0,"exists":"","*":"Ankylosing spondylitis"},{"ns":0,"exists":"","*":"Antibodies"},{"ns":0,"exists":"","*":"Antibody-drug conjugate"},{"ns":0,"exists":"","*":"Antigen"},{"ns":0,"exists":"","*":"Bacteria"},{"ns":0,"exists":"","*":"Biologics for immunosuppression"},{"ns":0,"exists":"","*":"Biology"},{"ns":0,"exists":"","*":"Biomedical"},{"ns":0,"exists":"","*":"Bioreactor"},{"ns":0,"exists":"","*":"Biosimilar"},{"ns":0,"exists":"","*":"Biosimilars"},{"ns":0,"exists":"","*":"Blockbuster drug"},{"ns":0,"exists":"","*":"Blood"},{"ns":0,"exists":"","*":"Blood plasma"},{"ns":0,"exists":"","*":"Breast cancer"},{"ns":0,"exists":"","*":"Breast milk"},{"ns":0,"exists":"","*":"CTLA-4"},{"ns":0,"exists":"","*":"Cardiology"},{"ns":0,"exists":"","*":"Cell (biology)"},{"ns":0,"exists":"","*":"Cell culture"},{"ns":0,"exists":"","*":"Cell therapy"},{"ns":0,"exists":"","*":"Center for Biologics Evaluation and Research"},{"ns":0,"exists":"","*":"Center for Drug Evaluation and Research"},{"ns":0,"exists":"","*":"Chemotherapy"},{"ns":0,"exists":"","*":"Chronic diseases"},{"ns":0,"exists":"","*":"Chronic renal failure"},{"ns":0,"exists":"","*":"Clean room"},{"ns":0,"exists":"","*":"Clinical trials"},{"ns":0,"exists":"","*":"Colony stimulating factors"},{"ns":0,"exists":"","*":"Crohn's disease"},{"ns":0,"exists":"","*":"Denileukin diftitox"},{"ns":0,"exists":"","*":"Dermatology"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Drug"},{"ns":0,"exists":"","*":"Egg cell"},{"ns":0,"exists":"","*":"Eli Lilly and Company"},{"ns":0,"exists":"","*":"Erythropoetin"},{"ns":0,"exists":"","*":"Erythropoietin"},{"ns":0,"exists":"","*":"Escherichia coli"},{"ns":0,"exists":"","*":"Etanercept"},{"ns":0,"exists":"","*":"Europe"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"European Union"},{"ns":0,"exists":"","*":"Factor IX"},{"ns":0,"exists":"","*":"Factor VIII"},{"ns":0,"exists":"","*":"Fecal microbiota transplant"},{"ns":0,"exists":"","*":"Federal Register"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Fusion protein"},{"ns":0,"exists":"","*":"Gastroenterology"},{"ns":0,"exists":"","*":"Gene therapy"},{"ns":0,"exists":"","*":"Genentech"},{"ns":0,"exists":"","*":"Genetic engineering"},{"ns":0,"exists":"","*":"Genetically modified"},{"ns":0,"exists":"","*":"Goat"},{"ns":0,"exists":"","*":"Golimumab"},{"ns":0,"exists":"","*":"Growth hormone"},{"ns":0,"exists":"","*":"HER2/neu"},{"ns":0,"exists":"","*":"Hepatitis B"},{"ns":0,"exists":"","*":"Horizontal gene transfer"},{"ns":0,"exists":"","*":"Hormones"},{"ns":0,"exists":"","*":"Human fertilization"},{"ns":0,"exists":"","*":"Humanized antibodies"},{"ns":0,"exists":"","*":"Humulin"},{"ns":0,"exists":"","*":"Hybridoma"},{"ns":0,"exists":"","*":"Immunoassays"},{"ns":0,"exists":"","*":"Immunoglobin"},{"ns":0,"exists":"","*":"Immunoglobulin"},{"ns":0,"exists":"","*":"Infliximab"},{"ns":0,"exists":"","*":"Insulin"},{"ns":0,"exists":"","*":"Interferons"},{"ns":0,"exists":"","*":"Interleukin"},{"ns":0,"exists":"","*":"Interleukin-2"},{"ns":0,"exists":"","*":"International Nonproprietary Name"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"Life"},{"ns":0,"exists":"","*":"Liquid chromatography"},{"ns":0,"exists":"","*":"List of pharmaceutical companies"},{"ns":0,"exists":"","*":"List of recombinant proteins"},{"ns":0,"exists":"","*":"Macromolecule"},{"ns":0,"exists":"","*":"Malignancy"},{"ns":0,"exists":"","*":"Mass spectrometry"},{"ns":0,"exists":"","*":"Medical Subject Headings"},{"ns":0,"exists":"","*":"Medical devices"},{"ns":0,"exists":"","*":"Microinjection"},{"ns":0,"exists":"","*":"Monoclonal antibodies"},{"ns":0,"exists":"","*":"Monoclonal antibody"},{"ns":0,"exists":"","*":"Moss"},{"ns":0,"exists":"","*":"Mycoplasma"},{"ns":0,"exists":"","*":"Nanobiopharmaceutics"},{"ns":0,"exists":"","*":"Neurology"},{"ns":0,"exists":"","*":"Nucleic acid"},{"ns":0,"exists":"","*":"Oncology"},{"ns":0,"exists":"","*":"Organ transplantation"},{"ns":0,"exists":"","*":"Passive immunization"},{"ns":0,"exists":"","*":"Patent"},{"ns":0,"exists":"","*":"Patents"},{"ns":0,"exists":"","*":"Patient Protection and Affordable Care Act"},{"ns":0,"exists":"","*":"Pharmaceutical drug"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Pharming (genetics)"},{"ns":0,"exists":"","*":"Photo-bioreactors"},{"ns":0,"exists":"","*":"Plant-made pharmaceuticals"},{"ns":0,"exists":"","*":"Plant tissue culture"},{"ns":0,"exists":"","*":"Polysaccharide"},{"ns":0,"exists":"","*":"Precursor (chemistry)"},{"ns":0,"exists":"","*":"Psoriasis"},{"ns":0,"exists":"","*":"Psoriatic arthritis"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Receptor antagonist"},{"ns":0,"exists":"","*":"Recombinant DNA"},{"ns":0,"exists":"","*":"Recombinant protein"},{"ns":0,"exists":"","*":"Recombinant proteins"},{"ns":0,"exists":"","*":"Regulatory agency"},{"ns":0,"exists":"","*":"Rheumatoid arthritis"},{"ns":0,"exists":"","*":"Rheumatology"},{"ns":0,"exists":"","*":"Semisynthesis"},{"ns":0,"exists":"","*":"Small molecules"},{"ns":0,"exists":"","*":"Somatic cell"},{"ns":0,"exists":"","*":"Specialty drugs"},{"ns":0,"exists":"","*":"Spermatozoon"},{"ns":0,"exists":"","*":"Stem cell therapy"},{"ns":0,"exists":"","*":"T-cell"},{"ns":0,"exists":"","*":"Tissue (biology)"},{"ns":0,"exists":"","*":"Tissue plasminogen activator"},{"ns":0,"exists":"","*":"Tissue transplant"},{"ns":0,"exists":"","*":"Total synthesis"},{"ns":0,"exists":"","*":"Trade name"},{"ns":0,"exists":"","*":"Transgenic"},{"ns":0,"exists":"","*":"Trastuzumab"},{"ns":0,"exists":"","*":"Tumor necrosis factor-alpha"},{"ns":0,"exists":"","*":"Tumour necrosis factor"},{"ns":0,"exists":"","*":"Ulcerative colitis"},{"ns":0,"exists":"","*":"United States"},{"ns":0,"exists":"","*":"United States Adopted Name"},{"ns":0,"exists":"","*":"United States patent law"},{"ns":0,"exists":"","*":"Ustekinumab"},{"ns":0,"exists":"","*":"Vaccine"},{"ns":0,"exists":"","*":"Vaccines"},{"ns":0,"exists":"","*":"Viral gene therapy"},{"ns":0,"exists":"","*":"Virus"},{"ns":0,"exists":"","*":"Whole blood"}],"templates":[{"ns":10,"exists":"","*":"Template:See also"},{"ns":10,"exists":"","*":"Template:Main article"},{"ns":10,"exists":"","*":"Template:Main"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:Federal Register"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:MeshName"},{"ns":10,"exists":"","*":"Template:MeSH name"},{"ns":828,"exists":"","*":"Module:Labelled list hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Main"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:String"}],"images":["Lock-green.svg","FreshFrozenPlasma.JPG"],"externallinks":["http://www.oxforddictionaries.com/us/definition/english/biological","http://www.nature.com/nbt/journal/v26/n7/box/nbt0708-743_BX3.html","//doi.org/10.1038/nbt0708-743","//www.ncbi.nlm.nih.gov/pubmed/18612293","http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm","//doi.org/10.18553/jmcp.2013.19.7.542","//www.ncbi.nlm.nih.gov/pubmed/23964615","https://www.nytimes.com/2015/07/16/business/specialty-pharmacies-proliferate-along-with-questions.html","https://courses.washington.edu/pharm542/Week4/slidesSpecialty%20Pharmacy%20%20Managed%20Care%20Strategies%200410.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000266.jsp","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000294.jsp","http://edocket.access.gpo.gov/2008/pdf/E8-19572.pdf","//www.ncbi.nlm.nih.gov/pubmed/18958946","http://www.musculoskeletalnetwork.com/arthritis/content/article/1145622/1562177","http://www.briskfox.com/open/years/2009_q1/do_v_c44751.php","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668","//doi.org/10.3390/ph5121393","//www.ncbi.nlm.nih.gov/pubmed/24281342","//doi.org/10.1038/nbt.1839","//www.ncbi.nlm.nih.gov/pubmed/21478841","//doi.org/10.1080/14712598.2018.1421169","//www.ncbi.nlm.nih.gov/pubmed/29285958","http://adisonline.com/pharmaceuticalmedicine/Abstract/2012/26030/The_US_Biosimilars_Act__Challenges_Facing.1.aspx","//doi.org/10.1007/bf03262388","http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf","//www.federalregister.gov/citation/75-FR-61497","http://www.gpo.gov/fdsys/pkg/FR-2010-10-05/pdf/2010-24853.pdf","https://web.archive.org/web/20060316164416/http://scientific.thomson.com/free/ipmatters/pii/8180019/","http://scientific.thomson.com/free/ipmatters/pii/8180019/","https://www.phrma.org/press-release/new-report-reveals-growth-trajectories-and-top-policy-factors-affecting-biopharmaceutical-innovation-and-growth","https://www.forbes.com/sites/erincarlyle/2012/06/27/blood-money-the-guys-who-trade-your-blood-for-profit/#2ec937e46884","http://www.spermdonorsaustralia.com.au/","//doi.org/10.1007/s00449-007-0151-y","//www.ncbi.nlm.nih.gov/pubmed/17701058","//doi.org/10.1038/80231","//www.ncbi.nlm.nih.gov/pubmed/11017040","http://www.isb.vt.edu/articles/apr0603.htm","http://news.bbc.co.uk/1/hi/sci/tech/5041298.stm","http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_63/dir_2003_63_en.pdf","https://www.cov.com/-/media/files/corporate/publications/2013/10/chapter4_key_regulatory_guidlines_for_the_development_of_biologics_in_the_united_states_and_europe.pdf","https://meshb.nlm.nih.gov/record/ui?name=Biological%20Products","http://bio.org/speeches/pubs/er/BiotechGuide.pdf","http://www.cptech.org/ip/health/biotech/genbio062001.pdf","http://www.psoriasis.org/treatment/psoriasis/biologics/about.php"],"sections":[{"toclevel":1,"level":"2","line":"Major classes","number":"1","index":"1","fromtitle":"Biopharmaceutical","byteoffset":5877,"anchor":"Major_classes"},{"toclevel":2,"level":"3","line":"Extracted from living systems","number":"1.1","index":"2","fromtitle":"Biopharmaceutical","byteoffset":6033,"anchor":"Extracted_from_living_systems"},{"toclevel":2,"level":"3","line":"Produced by recombinant DNA","number":"1.2","index":"3","fromtitle":"Biopharmaceutical","byteoffset":6696,"anchor":"Produced_by_recombinant_DNA"},{"toclevel":2,"level":"3","line":"Vaccines","number":"1.3","index":"4","fromtitle":"Biopharmaceutical","byteoffset":13227,"anchor":"Vaccines"},{"toclevel":2,"level":"3","line":"Gene therapy","number":"1.4","index":"5","fromtitle":"Biopharmaceutical","byteoffset":13312,"anchor":"Gene_therapy"},{"toclevel":1,"level":"2","line":"Biosimilars","number":"2","index":"6","fromtitle":"Biopharmaceutical","byteoffset":13452,"anchor":"Biosimilars"},{"toclevel":1,"level":"2","line":"Commercialization","number":"3","index":"7","fromtitle":"Biopharmaceutical","byteoffset":17547,"anchor":"Commercialization"},{"toclevel":1,"level":"2","line":"Large-scale production","number":"4","index":"8","fromtitle":"Biopharmaceutical","byteoffset":20401,"anchor":"Large-scale_production"},{"toclevel":2,"level":"3","line":"Transgenics","number":"4.1","index":"9","fromtitle":"Biopharmaceutical","byteoffset":21392,"anchor":"Transgenics"},{"toclevel":1,"level":"2","line":"Regulation","number":"5","index":"10","fromtitle":"Biopharmaceutical","byteoffset":23236,"anchor":"Regulation"},{"toclevel":2,"level":"3","line":"European Union","number":"5.1","index":"11","fromtitle":"Biopharmaceutical","byteoffset":23252,"anchor":"European_Union"},{"toclevel":2,"level":"3","line":"United States","number":"5.2","index":"12","fromtitle":"Biopharmaceutical","byteoffset":24789,"anchor":"United_States"},{"toclevel":1,"level":"2","line":"See also","number":"6","index":"13","fromtitle":"Biopharmaceutical","byteoffset":26041,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"14","fromtitle":"Biopharmaceutical","byteoffset":26214,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"8","index":"15","fromtitle":"Biopharmaceutical","byteoffset":26249,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Biopharmaceutical","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q679692"}]}}